We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$89.4M
Cap. Flow %
4.5%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Consumer Staples 0.19%
3 Consumer Discretionary 0.06%
4 Energy 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
CALL
DELISTED
Sage Therapeutics
SAGE
$21.9M 1.1%
275,000
+75,000
+38% +$5.42M
XLRN
27
DELISTED
Acceleron Pharma
XLRN
$21.6M 1.09%
711,259
+47,402
+7% +$1.37M
CTMX icon
28
CytomX Therapeutics
CTMX
$730M
$21.6M 1.08%
1,390,381
-140,278
-9% -$2.11M
DBVT
29
DBV Technologies
DBVT
$899M
$21.1M 1.06%
59,177
– –
KDMN
30
DELISTED
Kadmon Holdings, Inc.
KDMN
$20.2M 1.02%
5,185,847
– –
ISRG icon
31
Intuitive Surgical
ISRG
$130B
$19.4M 0.97%
+186,255
New +$17.9M
HUM icon
32
Humana
HUM
$47.6B
$18.8M 0.95%
78,093
+50,593
+184% +$11.5M
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$17.4M 0.88%
+845,000
New +$17.3M
LKFT
34
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$17.3M 0.87%
226,405
-45,000
-17% -$3.78M
RNAC icon
35
Cartesian Therapeutics
RNAC
$307M
$15.8M 0.8%
26,578
+21,849
+462% +$9.65M
AKBA icon
36
Akebia Therapeutics
AKBA
$248M
$15.8M 0.8%
1,100,000
+1,050,376
+2,117% +$13.3M
AVDL
37
DELISTED
Avadel Pharmaceuticals
AVDL
$15.8M 0.79%
1,429,114
+20,874
+1% +$210K
MYOK
38
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.5M 0.73%
553,154
-71,540
-11% -$943K
ATRS
39
DELISTED
Antares Pharma, Inc.
ATRS
$13.7M 0.69%
4,267,253
+1,350,000
+46% +$3.83M
BOLD
40
DELISTED
Audentes Therapeutics, Inc
BOLD
$13.5M 0.68%
707,500
+700,000
+9,333% +$11.2M
ALDX icon
41
Aldeyra Therapeutics
ALDX
$93.5M
$13.4M 0.68%
2,885,458
– –
AVEO
42
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$13.3M 0.67%
601,066
+90,185
+18% +$710K
JAZZ icon
43
Jazz Pharmaceuticals
JAZZ
$16.8B
$13.3M 0.67%
85,572
+55,572
+185% +$8.5M
SIOX
44
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$13.3M 0.67%
71,588
+32,838
+85% +$5.76M
WVE icon
45
Wave Life Sciences
WVE
$1.03B
$12.3M 0.62%
662,798
-2,400
-0.4% -$51.7K
IRTC icon
46
iRhythm Holdings
IRTC
$3.97B
$12M 0.6%
282,857
+11,800
+4% +$430K
ZYNE
47
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$10.2M 0.51%
+100,000
New +$1.99M
ARGX icon
48
argenx
ARGX
$65.5B
$9.54M 0.48%
+450,000
New +$9.37M
ARDX icon
49
Ardelyx
ARDX
$984M
$9.23M 0.46%
1,810,581
-75,615
-4% -$642K
ASMB icon
50
Assembly Biosciences
ASMB
$736M
$9.12M 0.46%
36,819
-18,544
-33% -$5.22M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $89.4M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.